Empagliflozin
Cardiometabolic drugs consume majority of cost among those up for price negotiation
Among the first 10 drugs selected for price negotiations under the 2022 Inflation Reduction Act, cardiometabolic medications consumed more than 80% of Medicare Part D spending, researchers reported.
Sodium-glucose inhibitor use in PAH may have mortality benefit
BOSTON — Fewer patients with pulmonary arterial hypertension died at three time points with use of a sodium-glucose cotransporter-2 inhibitor, according to data presented at the CHEST Annual Meeting.
Medicare announces price cuts for 10 drugs in first round of drug price negotiations
The Centers for Medicare & Medicaid Services announced lower Medicare Part D prices for 10 drugs that will take effect in 2026, according to a press release.
Semaglutide does not raise risk for neurologic disorders for adults with type 2 diabetes
Semaglutide was not associated with increased risks for adverse neurologic or psychological disorders at 1 year compared with other diabetes drugs, according to data published in eClinicalMedicine.
Q&A: Javed Butler, MD, MPH, MBA, discusses the current heart failure medication landscape
Few areas in cardiology are as active as development and implementation of medical therapies for heart failure, and few people are as familiar with that landscape as Javed Butler, MD, MPH, MBA, FACC, FAHA, FESC.
Part of the Healio Network
Sodium-Glucose Transporter 2 (SGLT2) Inhibitors Topic Review
As a class, sodium–glucose transporter 2 inhibitors are novel drugs initially developed for glycemic control in patients with type 2 diabetes. [Cowie MR, et al. Nat Rev Cardiol. 2020;1a]
Empagliflozin did not cut risk for death, HF hospitalization after heart attack: EMPACT-MI
ATLANTA — In the EMPACT-MI trial, empagliflozin treatment soon after an acute MI did not significantly lower risk for HF hospitalization or death from any cause compared with placebo among patients with increased risk for HF.
ACC to showcase ‘exceptional’ science, mark 75 years at upcoming scientific session
The 2024 American College of Cardiology Scientific Session will be held live in Atlanta from April 6 to 8 and virtually, with 43 late-breaking trials and featured clinical research presentations.
ACC announces late-breaking clinical trial lineup for 2024 Scientific Session
The American College of Cardiology announced the late-breaking science lineup for its Scientific Session to be held April 6-8 in Atlanta and online.
Kidney function decline slows in patients with diabetes on empagliflozin vs. placebo
Patients with type 2 diabetes and chronic kidney disease receiving empagliflozin were less likely to experience a decline in eGFR compared with patients taking placebo, results from a newly published study show.